Fulcrum Therapeutics, Inc. (FULC): A Bull Case Theory
We came across a bullish thesis on Fulcrum Therapeutics, Inc. (FULC) on Stock Pursuit's Substack. In this article, we will summarize the bulls' thesis on FULC. Fulcrum Therapeutics, Inc. (FULC)'s share was trading at $6.44 as of 23rd May. FULC's trailing P/E was 312.50 according to Yahoo Finance.
A scientist in a lab conducting research on cell-based therapeutics and biotechnology.
Fulcrum Therapeutics (FULC) recently surged over 110% from around $3.30 to $7.00, reflecting growing optimism but also presenting a prime opportunity to take profits. The company's lead candidate, Pociredir (FTX-6058), is an oral small molecule in Phase 1b trials aimed at treating Sickle Cell Disease (SCD) by increasing fetal hemoglobin expression. While early data are encouraging, larger trials are needed to confirm efficacy and safety, especially following a prior clinical hold related to concerns over EED inhibitors.
Analysts have raised their peak sales forecasts to roughly $600 million with a 50% probability of success, and Fulcrum's cash runway extends into 2027. Market dynamics favor Pociredir due to Pfizer's withdrawal of Oxbryta and slow adoption of gene therapies, creating scarcity value for new oral treatments. Beyond SCD, Fulcrum is developing programs for inherited aplastic anemias, with an Investigational New Drug application for Diamond-Blackfan anemia expected in late 2025. Despite this promise, history shows that small-cap pharma stocks can experience volatile reversals after big gains, so locking in profits while retaining a small position for potential upside on drug results seems prudent.
The broader biotech sector, historically avoided by the author, has recently become more attractive due to technological advances and compelling net cash positions, as demonstrated by previous successes like Somalogic. Overall, Fulcrum represents a high-risk, high-reward opportunity in a niche with growing unmet medical needs, but caution and disciplined profit-taking remain essential given the sector's volatility.
Fulcrum Therapeutics, Inc. (FULC) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 21 hedge fund portfolios held FULC at the end of the first quarter which was 23 in the previous quarter. While we acknowledge the risk and potential of FULC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than FULC but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure: None. This article was originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
19 minutes ago
- Washington Post
Brewers' Brandon Woodruff leaves rehab appearance after a line drive hits his right elbow
NASHVILLE, Tenn. — Milwaukee Brewers right-handed pitcher Brandon Woodruff took a line drive to his throwing elbow during a rehabilitation appearance with Triple-A Nashville on Tuesday. Woodruff left the game after getting struck by a batted ball from Gwinnett's Cade Bunnell that had a 108-mph exit velocity. Milwaukee manager Pat Murphy said after the Brewers' 4-2 loss in Cincinnati on Tuesday night that his understanding was that X-rays on Woodruff were negative. Murphy added that Woodruff would undergo a CT scan on Wednesday. The incident could cause one more delay in Woodruff's long-awaited return to the majors. The two-time All-Star last pitched in a major league game on Sept. 23, 2023. Woodruff missed the Brewers' 2023 postseason with a shoulder injury that required surgery and prevented him from pitching last year. He was pitching for Nashville and getting ready to get back to the big leagues last month when tendinitis in his right ankle slowed his return. ___ AP MLB:
Associated Press
22 minutes ago
- Associated Press
Brewers' Brandon Woodruff leaves rehab appearance after a line drive hits his right elbow
NASHVILLE, Tenn. (AP) — Milwaukee Brewers right-handed pitcher Brandon Woodruff took a line drive to his throwing elbow during a rehabilitation appearance with Triple-A Nashville on Tuesday. Woodruff left the game after getting struck by a batted ball from Gwinnett's Cade Bunnell that had a 108-mph exit velocity. Milwaukee manager Pat Murphy said after the Brewers' 4-2 loss in Cincinnati on Tuesday night that his understanding was that X-rays on Woodruff were negative. Murphy added that Woodruff would undergo a CT scan on Wednesday. The incident could cause one more delay in Woodruff's long-awaited return to the majors. The two-time All-Star last pitched in a major league game on Sept. 23, 2023. Woodruff missed the Brewers' 2023 postseason with a shoulder injury that required surgery and prevented him from pitching last year. He was pitching for Nashville and getting ready to get back to the big leagues last month when tendinitis in his right ankle slowed his return. ___ AP MLB:
Associated Press
22 minutes ago
- Associated Press
Angels manufacture run in 10th inning to beat Red Sox, 4-3
BOSTON (AP) — Automatic runner Zach Neto scored on Taylor Ward's bases-loaded double play groundout to lift the Los Angeles Angels to a 4-3 victory over the Boston Red Sox in 10 innings on Tuesday night. Nolan Schanuel had two RBIs and Neto added two hits and an RBI to give the Angels consecutive wins for the first time since capping an eight-game win streak on May 23. Kenley Jansen (1-2) pitched a scoreless ninth inning to pick up the win a night after getting a save and Reid Detmers got his first save. Schanuel led off the 10th with a sacrifice bunt that was bobbled by reliever Zack Kelly (1-2), allowing Neto to advance to third. Mike Trout then walked to load the bases. Kelly went 3-0 to Ward before he grounded into the double play. But it allowed Neto to score to put the Angels in front. Ceddanne Rafaela had two RBIs for Boston. Jarren Duran also had an RBI. Los Angeles starter Yusei Kikuchi pitched five innings plus three batters, allowing three runs off eight hits with five walks. He also struck out five, including his 900th major league strikeout. Boston's Brayan Bello ended a five-game streak of not making it through at least five innings. He lasted six innings, allowing three runs off seven hits. Key moment With Boston trailing 3-1 in the sixth, Trevor Story led off with a walk. Rafaela then jumped on Kikuchi's 89 mph slider, driving it 426 feet over the Green Monster for his fifth homer of the season. It was Kikuchi's final hitter of the night. Key stat Boston drops to 6-17 in one-run games this season. Up next Angels RHP José Soriano (4-5, 3.41 ERA) faces Red Sox RHP Lucas Giolito (1-1, 4.78) in the series finale. ___ AP MLB:
